Liquidia Co. (NASDAQ:LQDA) Stake Increased by Deutsche Bank AG

Deutsche Bank AG grew its position in shares of Liquidia Co. (NASDAQ:LQDA - Free Report) by 53.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 51,075 shares of the company's stock after buying an additional 17,790 shares during the period. Deutsche Bank AG owned about 0.06% of Liquidia worth $601,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in Liquidia by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 3,557,296 shares of the company's stock worth $41,834,000 after buying an additional 115,367 shares during the last quarter. LM Advisors LLC acquired a new stake in shares of Liquidia during the 4th quarter worth approximately $25,948,000. Geode Capital Management LLC raised its position in shares of Liquidia by 8.2% during the 4th quarter. Geode Capital Management LLC now owns 1,339,254 shares of the company's stock worth $15,753,000 after purchasing an additional 101,597 shares during the period. Invesco Ltd. raised its position in shares of Liquidia by 2,675.0% during the 4th quarter. Invesco Ltd. now owns 700,171 shares of the company's stock worth $8,234,000 after purchasing an additional 674,940 shares during the period. Finally, Northern Trust Corp raised its position in shares of Liquidia by 19.5% during the 4th quarter. Northern Trust Corp now owns 589,921 shares of the company's stock worth $6,937,000 after purchasing an additional 96,381 shares during the period. Institutional investors own 64.54% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. HC Wainwright increased their price target on Liquidia from $29.00 to $35.00 and gave the stock a "buy" rating in a research report on Wednesday, May 28th. Oppenheimer set a $13.00 target price on Liquidia and gave the company an "underperform" rating in a research report on Monday, May 19th. Wall Street Zen upgraded Liquidia from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Wells Fargo & Company raised their target price on Liquidia from $20.00 to $23.00 and gave the company an "overweight" rating in a research report on Wednesday, May 28th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $25.00 price target on shares of Liquidia in a research note on Wednesday, May 28th. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $26.67.

Liquidia Stock Up 13.1%

NASDAQ LQDA traded up $1.95 on Monday, reaching $16.87. 4,732,484 shares of the stock traded hands, compared to its average volume of 1,101,568. The firm's fifty day simple moving average is $14.75 and its 200 day simple moving average is $13.82. The company has a market cap of $1.44 billion, a price-to-earnings ratio of -10.35 and a beta of 0.24. Liquidia Co. has a 12 month low of $8.26 and a 12 month high of $19.41.

Liquidia (NASDAQ:LQDA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.03). The firm had revenue of $3.12 million for the quarter, compared to the consensus estimate of $3.23 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. As a group, equities research analysts forecast that Liquidia Co. will post -1.51 EPS for the current fiscal year.

Insider Transactions at Liquidia

In other news, CEO Roger Jeffs sold 14,130 shares of the firm's stock in a transaction on Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $191,744.10. Following the completion of the sale, the chief executive officer now directly owns 1,006,420 shares of the company's stock, valued at $13,657,119.40. This trade represents a 1.38% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Jason Adair sold 1,856 shares of the firm's stock in a transaction on Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $25,185.92. Following the sale, the insider now directly owns 184,304 shares of the company's stock, valued at approximately $2,501,005.28. This represents a 1.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 33,138 shares of company stock valued at $450,233 in the last three months. 26.50% of the stock is currently owned by corporate insiders.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).